Skip to main content

Full text of "USPTO Patents Application 10555896"

See other formats


AMENDMENTS TO THE CLAIMS 



1.-15. (Cancelled) 

16. (Original) A process for the identification of new uses of an active agent comprising 

the following steps: 

a) identifying a binding molecule for the active agent; 

b) identifying cellular binding partners of the binding molecule under physiological 
conditions, and 

c) identifying medical indications linked to one or more of the binding partners of 
step b). 

17. (New) The process according to claim 16, wherein said active agent is selected 
from the group consisting of a synthetic compound. 

18. (New) The process according to claim 17, wherein said active agent is a synthetic 
organic drug. 

19. (New) The process according to claim 1 8, wherein said active agent is a small 
molecule organic drug. 

20. (New) The process according to claim 16, wherein said active agent is an active 
agent of a pharmaceutical composition. 

21. (New) The process according to claim 16, wherein said active agent is selected 
from the group consisting of benserazide, sulindac or parthenolide. 

22. (New) The process according to claim 16, wherein in step a) said active agent is 
bound to a solid support material. 

23. (New) The process according to claim 16, wherein said binding molecule as 
defined in step a) is a protein that directly or indirectly binds to the active agent. 

24. (New) The process according to claim 16, wherein said binding molecule as 
defined in step a) is part of a sample derived from a mammal. 

2 



25. (New) The process according to claim 24, wherein said mammal is suffering from 
an impaired condition or disease. 

26. (New) The process according to claim 24, wherein said mammal is a human. 

27. (New) The process according to claim 26, wherein said human is suffering from an 
impaired condition or disease. 

28. (New) The process according to claim 27, wherein said impaired condition or 
disease is selected from cancer, neurodegenerative diseases, inflammatory diseases, 
AIDS, metabolic diseases, asthma, arteriosclerosis, coronary and heart diseases, and 
infectious diseases. 

29. (New) The process according to claim 28, wherein said neurodegenerative disease 
is Alzheimer's disease or Parkinson's disease. 

30. (New) The process according to claim 28, wherein said inflammatory disease is an 
allergy or rheumatoid arthritis. 

3 1 . (New) The process according to claim 28, wherein said metabolic disease is 
diabetes mellitus. 

32. (New) The process according to claim 16, wherein step a) is performed under 
physiological conditions. 

33. (New) The process according to claim 32, wherein said physiological conditions in 
step a) are selected from a physiological cellular protein concentration, a 
physiological pH value, a physiological buffer capacity, a physiological osmolarity, 
and a physiological temperature. 

34. (New) The process according to claim 16, wherein in step b) said cellular binding 
partners are identified at least in part by a technique selected from the group 
consisting of specific antibody binding, peptide-sequencing, Maldi-TOF mass- 
spectrometry, and electrospray-mass-spectrometry. 

3 



35. (New) The process according to claim 16, wherein said cellular binding partners as 
defined in step b) are proteins that directly or indirectly interact with the binding 
molecule. 

36. (New) The process according to claim 16, wherein said physiological conditions in 
step b) are selected from a physiological cellular protein concentration, a 
physiological pH value, a physiological buffer capacity, a physiological osmolarity, 
and a physiological temperature. 

37. (New) The process according to claim 16, wherein in step b) the binding molecule 
is provided and the binding of the cellular binding partners to the binding molecule 
is determined. 

38. (New) The process according to claim 16, wherein step b) is performed using the 
TAP purification technology. 

39. (New) The process according to claim 16, wherein said medical indications in step 
c) are selected the group consisting of cancer, neurodegenerative diseases, 
inflammatory diseases, AIDS, metabolic diseases, asthma, arteriosclerosis, coronary 
and heart diseases, and infectious diseases. 

40. (New) The process according to claim 39, wherein said neurodegenerative disease 
is Alzheimer's disease or Parkinson's disease, 

41 . (New) The process according to claim 39, wherein said inflammatory disease is an 
allergy or rheumatoid arthritis. 

42. (New) The process according to claim 39, wherein said metabolic disease is 
diabetes mellitus. 



4